<DOC>
	<DOCNO>NCT02473809</DOCNO>
	<brief_summary>The purpose study test whether liraglutide , drug approve widely use treatment type 2 diabetes , effect bone mass bone cell function . Type 2 diabetes may cause multiple complication , well know patient type 2 diabetes high risk fracture . If Liraglutide demonstrate positive effect bone , may one among factor consider decision specific treatment type 2 diabetes make individual patient .</brief_summary>
	<brief_title>The Effect Liraglutide Bone Turnover , Bone Mass Bone Cell Function</brief_title>
	<detailed_description>Background : Type 2 diabetes may cause complication ischemic heart disease , nephropathy , neuropathy , retinopathy . Several epidemiologic animal study also suggest fracture risk increase diabetes . Bone remodelled throughout life bone resorption bone resorb cell , osteoclast , bone formation bone form cell , osteoblast . Bone remodelling monitor biochemical marker bone turnover effect bone remodelling measure change bone mineral density ( BMD ) Dual X-ray absorptiometry ( DXA ) bone structure quantitative CT ( QCT ) high resolution peripheral QCT ( HRpQCT ) . The remodelling activity balance resorption formation influence many factor include food consumption . The gut hormone glucagon-like polypeptide 1 ( GLP-1 ) release relation food intake reduces serum level glucagon , increase serum level insulin , reduces blood glucose diabetes . Liraglutide GLP-1 analogue approve treatment type 2 diabetes . Aim : To investigate effect GLP-1 analogue Liraglutide bone turnover , bone mass , bone structure patient type 2 diabetes . Methods : The clinical study conduct randomise , double-blinded , placebo-controlled , prospective , clinical trial comparative treatment regime either subcutaneous Liraglutide subcutaneous placebo injection . Perspectives : The project bring new knowledge possible effect GLP-1 analogue bone turnover structure . This important give type 2 diabetes deteriorate bone health increase risk fracture . If Liraglutide demonstrate positive effect bone , may one among factor consider decision specific treatment type 2 diabetes make individual patient .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent Diagnosis type 2 diabetes ( HbA1c &gt; 48 mmol/mol ) Age old 30 year Type 1 diabetes Treatment insulin Body weight &gt; 140 kg HbA1c &gt; 75 mmol/mol Treatment GLP1 analogue , Dipeptidyl peptidase4 inhibitor , glitazones Chronic kidney disease Hepatic disease Pancreatitis Inflammatory bowel disease Osteoporosis Family personal history medullary thyroid carcinoma Treatment glucocorticoids Hormone replacement therapy Diabetic gastroparesis Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>